Roche hit with another key R&D setback as oral SERD flops in breast cancer
Roche’s oral SERD giredestrant has flunked a Phase II study for advanced breast cancer, raising fresh questions about the future of the field as well …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
